Royal Biologics acquired the FIBRINET system from Vertical Spine. This furthers Royal Biologics’ strategic initiative to add novel technologies to its portfolio of autologous and live cellular solutions to support orthopedic and spinal fusion. The company received funding in 2019 to support employee onboarding, operational growth, product development and acquisitions.
FIBRINET uses a patient’s own blood to create a platelet-rich fibrin matrix/membrane (PRFM). The patient’s autologous platelets are harvested first through centrifugation and then combined with a proprietary solution to solidify into a fibrin clot/membrane, which can be used to augment spinal fusion.
FIBRINET is reportedly the first commercialized system that utilizes a non-thrombin solution to create a reproducible PRFM.
Salvatore Leo, Royal Biologics Chief Executive Officer, said, “FIBRINET’S technology now allows surgeons to harvest a patient’s autologous cells and create a unique platelet-rich fibrin membrane-scaffold to be used at the point of care in most spinal fusion procedures. When added to our current product portfolio of autologous and live cellular therapies, we feel that providing each patient an opportunity to harvest their own unique cells for treatment is a superior option in many surgical settings.”
Royal Biologics acquired the FIBRINET system from Vertical Spine. This furthers Royal Biologics’ strategic initiative to add novel technologies to its portfolio of autologous and live cellular solutions to support orthopedic and spinal fusion. The company received funding in 2019 to support employee onboarding, operational growth, product...
Royal Biologics acquired the FIBRINET system from Vertical Spine. This furthers Royal Biologics’ strategic initiative to add novel technologies to its portfolio of autologous and live cellular solutions to support orthopedic and spinal fusion. The company received funding in 2019 to support employee onboarding, operational growth, product development and acquisitions.
FIBRINET uses a patient’s own blood to create a platelet-rich fibrin matrix/membrane (PRFM). The patient’s autologous platelets are harvested first through centrifugation and then combined with a proprietary solution to solidify into a fibrin clot/membrane, which can be used to augment spinal fusion.
FIBRINET is reportedly the first commercialized system that utilizes a non-thrombin solution to create a reproducible PRFM.
Salvatore Leo, Royal Biologics Chief Executive Officer, said, “FIBRINET’S technology now allows surgeons to harvest a patient’s autologous cells and create a unique platelet-rich fibrin membrane-scaffold to be used at the point of care in most spinal fusion procedures. When added to our current product portfolio of autologous and live cellular therapies, we feel that providing each patient an opportunity to harvest their own unique cells for treatment is a superior option in many surgical settings.”
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
